Downregulation of short‐stature homeobox protein 2 suppresses gastric cancer cell growth and stemness in vitro and in vivo via inactivating wnt/β‐catenin signaling DOI Open Access
Xiangyu Chen, Shuai Li,

Binghua Sun

и другие.

Drug Development Research, Год журнала: 2024, Номер 85(7)

Опубликована: Окт. 17, 2024

Abstract Gastric cancer (GC) a prevalent form of globally. Previous research suggests that SHOX2 may have role in promoting progression. However, the GC is not well understood. Based on data from TCGA_GC set, SHXO2 levels were examined normal and tissues. Patients cohort divided into high‐ low‐SHOX2 level groups for analysis overall survival (OS), functional enrichment, immune infiltration. Furthermore, experiments conducted to investigate impact cell function through gain‐ loss‐of‐function experiments. Utilizing public databases, mRNA found be elevated tissues compared control, this finding was confirmed by RT‐qPCR, western blot analysis, immune‐histochemical analyses. Elevated could serve as an independent indicator poor prognosis patients. had negative correlation with CD8 T cells CD4 memory activated cells, positive M0 macrophages Functional analyses revealed deficiency notably suppressed proliferation, migration, invasion. Additionally, shown suppress stemness vitro vivo via inactivating wnt/β‐catenin signaling. Collectively, prognostic marker patients, downregulation effectively impede growth signaling pathway. These findings underscore potential promising therapeutic target GC.

Язык: Английский

CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review) DOI Creative Commons

Dahua Sun,

Xiang Shi, Sanyan Li

и другие.

Molecular Medicine Reports, Год журнала: 2024, Номер 29(3)

Опубликована: Янв. 23, 2024

Chimeric antigen receptor (CAR)‑T cell therapy is an innovative approach to immune that works by modifying the T cells of a patient express CAR protein on their surface, and thus induce recognition destruction cancer cells. CAR‑T has shown some success in treating hematological tumors, but it still faces number challenges treatment solid such as selection, tolerability safety. In response these issues, studies continue improve design pursuit improved therapeutic efficacy future, expected become important treatment, may provide new ideas strategies for individualized immunotherapy. The present review provides comprehensive overview principles, clinical applications, therapy.

Язык: Английский

Процитировано

21
CAR-T cell therapy: a game-changer in cancer treatment and beyond DOI
Kumar Utkarsh, Namita Srivastava, Sachin Kumar

и другие.

Clinical & Translational Oncology, Год журнала: 2024, Номер 26(6), С. 1300 - 1318

Опубликована: Янв. 20, 2024

Язык: Английский

Процитировано

11
Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis DOI Open Access
Kai Liu, Chunxiao Wu, Hui Liang

и другие.

World Journal of Gastrointestinal Surgery, Год журнала: 2024, Номер 16(3), С. 700 - 709

Опубликована: Март 21, 2024

Gastric cancer (GC) is the fifth most common type of and has fourth highest death rate among all cancers. There a lack studies examining impact liver metastases on effectiveness immunotherapy in individuals diagnosed with GC.

Язык: Английский

Процитировано

11
Preclinical application of a CD155 targeting chimeric antigen receptor T cell therapy for digestive system cancers DOI
Kai Zhang,

Yang Mi,

Bohao Zhang

и другие.

Oncogene, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

2
HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy DOI Creative Commons
Qiang Shao,

Junge Deng,

Haoran Wu

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Март 13, 2025

Gastric cancer (GC) ranks as the fifth most prevalent on a global scale, with HER2-positive GC representing distinct subtype that exhibits more intricate biological characteristics. Conventional chemotherapy typically restricted efficacy in management of GC. In light incessant advancement molecular targeted therapies, targeting HER2 has emerged promising therapeutic approach for this subtype. The advent antibody-drug conjugates (ADCs) and chimeric antigen receptor T-cell therapy (CAR-T) furnished novel treatment alternatives Nevertheless, owing to pronounced heterogeneity complex tumor microenvironment, drug resistance frequently emerges, thereby substantially influencing effectiveness HER2-targeted therapy. This article comprehensively summarizes deliberates upon strategies well underlying mechanisms.

Язык: Английский

Процитировано

2
HER2+ advanced gastric cancer: Current state and opportunities (Review) DOI Creative Commons
Hui-Hui Hu,

Saiqi Wang,

Huichen Zhao

и другие.

International Journal of Oncology, Год журнала: 2024, Номер 64(4)

Опубликована: Фев. 19, 2024

Human epidermal growth factor receptor 2 (HER2)

Язык: Английский

Процитировано

9
Immunotherapy of gastric cancer: Present status and future perspectives DOI Creative Commons
John K. Triantafillidis,

Manousos M. Konstadoulakis,

Αpostolos Papalois

и другие.

World Journal of Gastroenterology, Год журнала: 2024, Номер 30(8), С. 779 - 793

Опубликована: Фев. 26, 2024

In this editorial, we comment on the article entitled "Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric clinical trial review (1999-2023)," which was published recent issue of

Язык: Английский

Процитировано

7
Advances in Immunotherapy and Targeted Therapy for Gastric Cancer: A Comprehensive Review DOI
Hui Yuan, Miao Bao, M. Chen

и другие.

British Journal of Hospital Medicine, Год журнала: 2025, Номер 86(3), С. 1 - 24

Опубликована: Март 26, 2025

Gastric cancer remains one of the most prevalent and lethal malignancies worldwide, characterized by poor survival rates, particularly in advanced stages. In recent years, a paradigm shift gastric treatment has been witnessed with introduction immunotherapy targeted therapies. This review provides detailed examination current immunotherapeutic strategies, including adoptive cell therapy (ACT), immune checkpoint inhibitors (ICIs), vaccines. Additionally, it explores advancements therapies, focusing on human epidermal growth factor receptor 2 (HER2) vascular endothelial (VEGFR) signaling pathways, as well emerging targets such claudin 18.2. Clinical trials investigating chimeric antigen T-cell (CAR-T) therapy, receptor-engineered (TCR-T) natural killer (NK) cell-based treatments have shown promise, when combined conventional chemotherapeutic regimens. However, challenges cytokine release syndrome, immune-related toxicities, scalability issues remain significant. The combination therapies represents promising approach to enhance outcomes. Future directions emphasize need overcome resistance mechanisms refine strategies improve efficacy while reducing adverse effects. aims elucidate landscape explore their potential shaping future clinical management for this devastating disease.

Язык: Английский

Процитировано

1
Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer–Narrative Review DOI Open Access
Agata Poniewierska-Baran,

Karolina Sobolak,

Paulina Niedźwiedzka‐Rystwej

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(12), С. 6471 - 6471

Опубликована: Июнь 12, 2024

Due to its rapid progression advanced stages and highly metastatic properties, gastric cancer (GC) is one of the most aggressive malignancies fourth leading cause cancer-related deaths worldwide. The process includes local invasion, metastasis initiation, migration with colonisation at distant sites, evasion immune response. Tumour growth involves activation inhibitory signals associated response, also known as checkpoints, including PD-1/PD-L1 (programmed death 1/programmed ligand 1), CTLA-4 (cytotoxic T cell antigen 4), TIGIT (T immunoreceptor Ig ITIM domains), others. Immune checkpoint molecules (ICPMs) are proteins that modulate innate adaptive responses. While their expression prominent on cells, mainly antigen-presenting cells (APC) other types they expressed tumour cells. engagement receptor by crucial for inhibiting or stimulating cell, which an extremely important aspect immunotherapy. This narrative review explores immunotherapy, focusing ICPMs inhibitors in GC. We summarise current clinical trials evaluating a target GC treatment.

Язык: Английский

Процитировано

4
Mapping the landscape of gastric cancer immunotherapy: Bibliometric insights into advances and hotspots DOI
Zhen Yuan,

Jing-Hang Wang,

Hao Cui

и другие.

World Journal of Gastrointestinal Oncology, Год журнала: 2025, Номер 17(3)

Опубликована: Фев. 13, 2025

BACKGROUND Immunotherapy has surfaced as a promising therapeutic modality for gastric cancer (GC). A comprehensive review of advancements, current status, and research trends in GC immunotherapy is essential to inform future investigative efforts. AIM To delineate the trends, focal points GC. METHODS We performed bibliometric analysis 2906 articles English concerning published from 2000 December 20, 2023, indexed Web Science Core Collection. Data visualization were facilitated by CiteSpace (6.1.6R), VOSviewer v.1.6.17, GraphPad Prism v8.0.2. RESULTS There been an increase annual publication rate research. China leads volume, while United States demonstrates highest citation impact. Fudan University notable its frequency output. Co-citation keyword revealed highlighted focus on prognosis, tumor microenvironment (TME), integrative with targeted therapy. Emerging areas include gastroesophageal junction cancer, adoptive immunotherapy, role Treg cell immunotherapy. CONCLUSION expanding field attracting considerable scientific interest. With clinical adoption GC, primary goals are enhance treatment efficacy patient outcomes. Unlike hematological malignancies, GC's solid TME presents distinct immunological challenges that may attenuate cytotoxic effects immune cells cells. For instance, although CAR-T therapy effective it underperformed settings. Current centered overcoming immunosuppression within TME, combinations therapy, dynamics, precise prognosis prediction Additionally, immunotherapy's treating become novel focus.

Язык: Английский

Процитировано

0